You are here: Industry Insights > Spinraza

News List

ICER says price for Biogen's Spinraza, estimated value for Novartis' Zolgensma are too high firstwordpharma
April 04, 2019
The Institute for Clinical and Economic Review (ICER) on Wednesday issued a final report indicating that Biogen……
China National Medical Products Association Approves SPINRAZA americanpharmaceuticalreview
March 01, 2019
Biogen announced that SPINRAZA has been approved by the China National Medical Products Association for the treatment of 5q spinal muscular atrophy,expanding the company’s presence in China.
NICE cost watchdogs spurn Biogen's pricey Spinraza but leave door open for a deal fiercepharma
August 15, 2018
Biogen’s spinal muscular atrophy drug Spinraza is picking up steam in the U.S. and beyond, but in the U.K., cost-effectiveness watchdogs have found it too expensive to endorse.
Draft guidelines reject NHS funding for Biogen’s Spinraza pharmatimes
August 15, 2018
The National Institute for Health and Care Excellence is not recommending NHS use of Biogen’s Spinraza for the rare genetic disorder spinal muscular atrophy (SMA) at this time.
Biogen's Spinraza zooms through blockbusterland, but analysts are fixated on Alzheimer's data fiercepharma
July 25, 2018
Biogen's Spinraza took a 100% leap and its multiple sclerosis franchise mostly held its own in the second quarter, but analysts weren't much interested in those topics on Tuesday morning's earnings call.
Five therapies endorsed for use on NHS Scotland pharmatimes
July 09, 2018
A new treatment option for the very rare condition infantile onset 5q spinal muscular atrophy (type I SMA) is among five medicines that have been endorsed by Scottish cost regulators for use on the NHS.
Gene therapy medication brings improvements in patients with severe SMA europeanpharmaceuticalreview
February 28, 2018
Spinraza, the gene therapy medication, also provides significant improvements in cases with the next most severe form of the spinal muscular atrophy…
Spinraza approved in the EU as first treatment for spinal muscular atrophy cphi-online
June 06, 2017
Robust data from Phase III studies demonstrated positive impact on motor milestone achievement; increased survival in infants with SMA.

Previous page 1 2 Next page